Overview
- UC Berkeley researchers published the study in Science Advances showing that TOFA improved multiple metabolic measures in mice, with the paper released Friday.
- TOFA works by inhibiting acetyl‑CoA carboxylase (ACC) and activating PPARα and PPARδ, which together turned on gene programs that raise energy use by as much as 18 percent in the animals.
- Treated obese mice lost fat and showed better insulin sensitivity, improved glucose control, lower triglycerides and signs of less fatty liver without significant loss of lean muscle.
- When given alongside GLP‑1 drugs such as semaglutide and tirzepatide in mice, TOFA produced larger gains in weight, glucose and triglyceride measures than either therapy alone, suggesting a complementary role.
- The team has formed ReRx Therapeutics to pursue development, but TOFA remains preclinical and must clear human safety, cardiovascular and long‑term efficacy tests before it can be considered as a treatment option.